Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm - Wikidata - wikimedia - TriplyDB

Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm

Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm

http://www.wikidata.org/entity/Q36755080

about

Lymphangioleiomyomatosis: differential diagnosis and optimal management Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.Diffuse Cystic Lung Disease. Part I.Extrapulmonary lymphangioleiomyoma: clinicopathological analysis of 4 cases A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness Development of ATAQ-LAM: a tool to assess quality of life in Lymphangioleiomyomatosis.Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis Genomic rearrangements in sporadic lymphangioleiomyomatosis: an evolving genetic story.Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Study of breast cancer incidence in patients of lymphangioleiomyomatosis.Incidental Nodal Lymphangioleiomyomatosis Is Not a Harbinger of Pulmonary Lymphangioleiomyomatosis: A Study of 19 Cases With Evaluation of Diagnostic Immunohistochemistry.NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2 SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.Pelvic lymphangioleiomyomatosis treated successfully with everolimus: Two case reports with literature review.Update in diffuse parenchymal lung disease 2012.Diffuse cystic lung diseases.Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.Spontaneous pneumothorax in diffuse cystic lung diseases.An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010).Regional Sparing in an Oligemic Lung Segment Supports Hematogenous Spread as a Pathogenic Mechanism in Lymphangioleiomyomatosis.Reply: Characterization of lymphangioleiomyomatosis as a neoplastic disease Genetic heterogeneity of circulating cells from patients with lymphangioleiomyomatosis with and without lung transplantation.In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.Profuse coarse pulmonary nodules in a patient with lymphangioleiomyomatosis: thirty-three years of follow-up.To be or not to be a neoplasm: what is lymphangioleiomyomatosis? Are we calling it what it really is?Emerging Roles for VEGF-D in Human Disease.Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.Chronic sirolimus therapy for lymphangioleiomyomatosis.Emerging biomarkers of lymphangioleiomyomatosis.Effect of beta-agonists on LAM progression and treatment.

P2860

Q27022412-B71D016D-A55F-4950-B7EA-39EF9FC96508 Q33587163-6C530CA9-5727-4098-9384-5EDAC820D6F5 Q33720145-BAEAA67A-B5DE-4AA3-943B-6A11C5229287 Q33722950-4CEAD16A-D998-47CA-B725-0ECE8E825235 Q33864955-F29FAB05-6788-4CA4-8C51-7665AAE83F9D Q34061748-C9F51AF0-C480-48D5-BFBE-4ADD8BFCC96B Q34380247-8CA82803-DC08-45F1-AB8C-2F74A0BCCA2C Q34924914-2210B591-3E45-4DA2-91C5-E34D97D567FB Q35074335-3F35F649-F193-4E3A-8012-4B72F291FD31 Q35689467-63D5E463-5332-4152-9DED-79C2DEF01DBF Q35899242-27DA4E70-0D18-4998-90AA-21D3749A29EB Q35971499-DB779D56-C4AE-4470-AA80-6E339926CCA5 Q36382124-71A7B7AC-35CD-4EF8-A216-586234574CAE Q36413204-30A4793E-5990-4A87-96B1-4743675782DD Q36462100-47F37AC0-F35A-415C-A6EE-9B4547DCD76C Q36678521-64931863-9B9A-43CC-B360-6E3267ACCC96 Q37158170-A41B4E91-AA10-49B0-8951-4BC697B9E6E7 Q37316220-7F38021D-352A-45DB-AA61-52FD2F977F58 Q37417526-CB1D7F5A-E5AA-4A1E-B8C8-8E219685AF40 Q37483111-1AEF09B5-0B43-49C9-8F65-AF84F3D8F8F4 Q37641575-F0E7027C-95F5-4010-AAA9-4C9C7F86AC24 Q37691961-42C82F2E-D713-4DB7-BA8F-7DC645E8D22E Q37696810-D16896D9-56B7-4750-BAF0-49B8D68377FF Q38103298-59388ED5-0E04-4162-9B1E-2AD6717FBADE Q38105975-817D7752-3578-4019-AC63-E26D387A2A2E Q38535992-9B2003CD-F523-4E94-9F48-D318EE466B6C Q38673770-9E5CF4EE-44D1-4C0D-B110-1417866AE658 Q40956977-9C1DDD99-5344-4AF2-8C60-FFACECAE6FB2 Q42340242-49922E86-4242-4E73-9E05-2CACF6AD45BF Q42345459-3C640061-B13F-4671-8291-156BF4693C76 Q42592422-740A707F-CA90-433B-9EA5-F059DBC78F89 Q42645301-66B0ED10-530B-41BD-A987-879A785A4E3E Q42929523-EA6920CB-325B-437A-9A12-F718B56334AC Q45378198-3FC44099-6351-4067-99FF-3709406CB4F1 Q47233157-B470F0A1-E206-4D5E-AE44-39A152809D5E Q47370738-3A9906D4-1E14-4F0E-8BDB-40BEC8C6B19A Q47758863-034E0186-616D-49FE-9179-77D12CD4D18C Q48008829-4A1AA8B0-C1EE-4E47-AC67-ABCD38D9E92B Q49679457-2EC5A9F0-7828-4296-9213-B1D57852E8D9 Q50020089-5F2AA69A-18EF-4CA3-9B85-42FBEA7CB22B

P2860

Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm

http://www.wikidata.org/entity/Q36755080

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Lymphangioleiomyomatosis: call ...... uctive, metastasizing neoplasm

@ast

Lymphangioleiomyomatosis: call ...... uctive, metastasizing neoplasm

@en

type

label

Lymphangioleiomyomatosis: call ...... uctive, metastasizing neoplasm

@ast

Lymphangioleiomyomatosis: call ...... uctive, metastasizing neoplasm

@en

prefLabel

Lymphangioleiomyomatosis: call ...... uctive, metastasizing neoplasm

@ast

Lymphangioleiomyomatosis: call ...... uctive, metastasizing neoplasm

@en

P1433

Q36755080-F19E07A5-F7A8-4CE2-B592-1197BA9921C4

P1476

Q36755080-0B316B78-5D49-48FF-AAED-2674DFCF0E51

P2093

Q36755080-3FAAA94F-7B2C-43A5-BE93-40864B7161B6

Q36755080-46E254A7-5D5C-4310-BDB4-125E46496825

Q36755080-B17C944A-1EE8-4554-BD17-51712F1BCB25

Q36755080-CEFB89F5-7DE3-4ACA-B22D-764B159F1F17

P2860

Q36755080-0A17E004-4A7A-498E-9953-65D6191C7E88

Q36755080-0BDD1495-6E77-4B1B-8BFB-4CD906CDCC45

Q36755080-0CFA2267-286B-42EC-96A7-9751698DF163

Q36755080-1CA6F0E8-E7A2-429B-939A-0300F08FB9AF

Q36755080-4B03D058-24A9-4EAA-993C-60DEB19C5AB3

Q36755080-5F5D2785-E692-469D-9E4A-8D8D27600A3A

Q36755080-61CFEA35-77B0-4E7B-9922-C4754B52BC8F

Q36755080-702D93FB-4A82-42EB-AC46-865DE136586F

Q36755080-8911B823-B4C0-4307-A21A-38F1A4F2B7A4

Q36755080-9CE5A796-A5B2-4B1B-8726-538F223B8534

P304

Q36755080-829D5A9E-3348-4773-9FEB-09750699AD87

P31

Q36755080-0173656F-5D25-4B0A-96E1-0E0C76EAF25C

P356

Q36755080-2D8B90F7-70E5-42BA-986B-1C321FF04368

P407

Q36755080-582CEFF8-FEDE-400A-89FB-F79883DFA71D

P433

Q36755080-C26091C9-55F2-4AD5-A9C3-202E4C20601F

P478

Q36755080-9EA314E0-11CB-41A8-BAAD-D6B79DC41D6D

P50

Q36755080-C6342B01-828D-4F75-BA1F-666F68964293

P577

Q36755080-98BE3BF4-3477-47EA-9E72-173C2DC00378

P698

Q36755080-D05F6606-8535-4DFF-A610-FB03B53808C8

P932

Q36755080-F0C7F8A1-3C03-4BBC-A7E7-14D9587A0F09

P356

RCCM.201205-0848OE

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Lymphangioleiomyomatosis: call ...... uctive, metastasizing neoplasm

@en

P2093

Elizabeth P Henske

http://www.w3.org/2001/XMLSchema#string

Joel Moss

http://www.w3.org/2001/XMLSchema#string

Thomas V Colby

http://www.w3.org/2001/XMLSchema#string

William D Travis

http://www.w3.org/2001/XMLSchema#string

P2860

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

Metastasis of benign tumor cells in tuberous sclerosis complex.

Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis.

Dysregulation of the TSC-mTOR pathway in human disease.

Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism.

Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis

Lymphangioleiomyomatosis - a wolf in sheep's clothing.

P304

1210-1212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201205-0848OE

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

186

http://www.w3.org/2001/XMLSchema#string

P50

Francis Mccormack

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23250499

http://www.w3.org/2001/XMLSchema#string

P932

3622443

http://www.w3.org/2001/XMLSchema#string